Trials / Completed
CompletedNCT06696807
Immunomodulatory Therapy & VSA
The Effects of Immunomodulatory Therapy in Patients with Vasospastic Angina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- Dao Wen Wang · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Vasospastic angina (VSA) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion. Although vasodilator therapy is widely used and significantly alleviates VSA symptoms, it has not led to notable improvements in the prognosis of patients with VSA. Recent studies have suggested that inflammation plays a crucial role in VSA. This study aimed to evaluate the potential effectiveness of immunomodulatory therapy for improving patient prognosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glucocorticosteroids and/or intravenous immunoglobulin | methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2024-04-01
- Completion
- 2024-05-01
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06696807. Inclusion in this directory is not an endorsement.